Navigation Links
Medinox Announces Clinical Results of Naproxen Prodrug
Date:5/26/2009

SAN DIEGO, May 26 /PRNewswire/ -- Medinox, Inc. (Carlsbad, CA) and its development partner, Logical Therapeutics, Inc. (Waltham, MA) announced the results of a double-blind, randomized, active comparator study of LT-NS001 (formerly MX-1094) vs naproxen, in subjects 45 to 70 years of age. LT-NS001 is a novel, patented NCE prodrug of the popular non-steroidal anti-inflammatory drug (NSAID) naproxen, which is being developed to significantly reduce the GI safety risks, including the formation of ulcers, associated with naproxen. Naproxen is widely regarded as the NSAID with the most favorable cardiovascular safety profile among all of the drugs in this class.

In this study, subjects underwent upper endoscopies at baseline and on day seven. Subjects receiving LT-NS001 experienced statistically significantly fewer endoscopically confirmed gastric ulcers compared to subjects receiving naproxen.

LT-NS001 is pharmacologically inactive as an NSAID in the GI tract, but once absorbed into the blood stream, it is converted rapidly and quantitatively to naproxen. It is being developed to provide therapeutic levels of naproxen while avoiding high local concentrations of naproxen in the GI tract, thereby reducing the local GI toxicity associated with conventional naproxen.

LT-NS001 has been studied in various randomized controlled single-dose and multiple-dose clinical studies. In all cases, there were no serious adverse events and LT-NS001 was well tolerated. Moreover, when the subjects were dosed twice daily with LT-NS001, plasma concentrations of naproxen were within the therapeutic range.

NSAIDs are the most common medications taken worldwide for the treatment of pain, inflammation, fever and arthritics, including both rheumatoid arthritis (RA) and osteoarthritis (OA). The use of NSAIDs is associated with serious side effects, the most frequent being an increased rate of gastric and duodenal ulcers. In the United States alone, the direct costs of treating ulcer complications associated with NSAID use exceed $4 billion a year. Serious NSAID-induced GI complications such as hemorrhage and perforation are directly responsible for about 20,000 deaths per year in the United States.

About Medinox, Inc.

Medinox, based in Carlsbad, CA, is a privately held biotechnology company, focused on developing novel therapeutic drugs for treating inflammation and septic shock. For more information about Medinox and its products, visit the company's website at www.medinox.com., or contact Monte Lai, Ph.D., President & CEO of Medinox, Inc. at cslai@medinox.com.

About Logical Therapeutics, Inc.

Based in Waltham, MA, Logical Therapeutics Inc. is a venture-backed, privately held biotechnology company focused on the development of products that treat diseases associated with inflammation. Logical's investors include SV Life Sciences, Burrill and Company, Novo Ventures A/S and Novitas Capital. For more information on Logical Therapeutics, visit the company's website at www.logicaltherapeutics.com.


'/>"/>
SOURCE Medinox, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Healthy Rebates, Inc. Announces the Launch of My HSA Rewards
2. Pro-cell Announces a Knock at the Door of Emerging Markets
3. March of Dimes Announces Nursing Scholarship Recipients
4. The Gout & Uric Acid Education Society (GUAES) Announces New Survey Results Highlighting Major Gaps in Public Awareness of Gout
5. AIM Health Group Inc. reports largest quarterly profit since going public and announces filing of financial results for the three months ended March 31, 2009 on SEDAR
6. Cephalon Announces Exercise of $65 Million Over-allotment Option on 2.50% Convertible Senior Subordinated Notes
7. QLT Announces Court Response to Motion to Dismiss and Removal of Case to Federal Court
8. Authentidate Holding Corp. Announces Results From Annual Meeting of Stockholders
9. Secretary Shinseki Announces $215 Million in Projects for Rural Veterans
10. Perot Systems Announces Special Financing Options for Stimulus Plan Healthcare Technology Upgrades
11. Medstrat Announces Integration of Echoes With MacPractices EMR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2017)... ... , ... Harbour , a DAO (decentralized autonomous organization) that harnesses the ... their technical specifications . , 2017 has seen an explosion of token launches ... which offerings will garner the greatest ROI. Dean Eigenmann, Co-founder and CEO of Harbour, ...
(Date:6/27/2017)... , ... June 27, 2017 , ... A January 18th ... projected to reach a staggering $6.81 billion by the year 2024 according to a ... a faster rate than those made from titanium. Los Angeles area clinic Beverly Hills ...
(Date:6/27/2017)... ... June 27, 2017 , ... Drs. Gregory Toback and ... in Mystic, CT. Covering the process and maintenance strategies of gum grafting and ... periodontal procedures. Drs. Toback and Urbanski practice as experienced periodontists in ...
(Date:6/27/2017)... Los Angeles, CA (PRWEB) , ... June 27, 2017 , ... ... on what crooked bites can indicate about early life experiences. What happens to a ... study reveals that stresses after birth can also take a toll on a baby’s ...
(Date:6/26/2017)... ... June 26, 2017 , ... The Centers for Advanced Orthopaedics ... of Richard Robinson as chief operating officer (COO). In this role, Robinson brings ... track record of simplifying business processes and developing growth strategies to increase market ...
Breaking Medicine News(10 mins):
(Date:6/9/2017)... , June 9, 2017 AirXpanders, Inc. (ASX: ... on the design, manufacture, sale and distribution of the ... the progress of its commercial roll-out in ... in more than one hundred (100) medical institutions and ... AeroForm offers a needle-free alternative for women who choose ...
(Date:6/7/2017)... , June 7, 2017 Endo International ... June 7, 2017, the Hon. Joseph R. Goodwin ... of West Virginia , entered a ... Inc. Pelvic Repair System Products Liability Litigation (the "MDL") ... MDL cases to provide expert disclosures on specific causation ...
(Date:6/3/2017)... 3, 2017  Eli Lilly and Company (NYSE: ... from the Phase 3 MONARCH 2 study showed ... inhibitor, in combination with fulvestrant, significantly improved progression-free ... in women with hormone-receptor-positive (HR+), human epidermal growth ... have relapsed or progressed after endocrine therapy (median ...
Breaking Medicine Technology: